Watch this on-demand webinar from InSphero, PharmaNest, and Icahn School of Medicine at Mount Sinai exploring why anti-fibrotic therapies remain critical in the GLP-1 era for MASH.
Learn how advanced 3D human in vitro models and AI-driven digital pathology are helping improve translational fibrosis assessment, better capture fibrosis biology, and support the development of next-generation MASH therapies.
